Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities

被引：2
|
作者：
Dimopoulos, Meletios A. [1 ]
Kastritis, Efstathios [1 ]
Christoulas, Dimitrios [1 ]
Migkou, Magdalini [1 ]
Gavriatopoulou, Maria [1 ]
Gkotzamanidou, Maria [1 ]
Iakovaki, Marina [1 ]
Roussou, Maria [1 ]
Efstathiou, Eleni [1 ]
Terpos, Evangelos [1 ]
机构：
[1] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
10.1182/blood.V114.22.958.958
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：395 / 396
页数：2
相关论文
共 50 条
  • [21] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [22] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [23] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [24] Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
    Chang, Hong
    Trieu, Young
    Qi, Xiaoying
    Xu, Wei
    Stewart, Keith A.
    Reece, Donna
    LEUKEMIA RESEARCH, 2007, 31 (06) : 779 - 782
  • [25] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [26] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [27] The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Bahlis, Nizar J.
    Song, Kevin W.
    Fu, Tommy
    Roland, Birgitte J.
    Chang, Hong
    Horsman, Doug
    Mansoor, Adnan
    Chen, Christine
    Masih-Khan, Esther
    Trieu, Young
    Bruyere, Helene
    Stewart, Douglas A.
    Reece, Donna E.
    BLOOD, 2008, 112 (11) : 610 - 610
  • [28] Our Experience of Using Lenalidomide, Bortezomib and Dexamethasone (RVD) Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Pogosyan, Gayane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S340 - S341
  • [29] Patient eligibility for lenalidomide/dexamethasone treatment in relapsed/refractory multiple myeloma
    Palumbo, A.
    Dimopoulos, M.
    San Miguel, J.
    Harousseau, J. L.
    Attal, M.
    Hussein, M.
    Knop, S.
    Ludwig, H.
    Sonneveld, P.
    von Lilienfeld-Toal, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 97 - 97
  • [30] Impact of Chromosome 1 Abnormalities on Outcome among Patients with Refractory/Relapsed Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone
    Qi, C.
    Trieu, Y.
    Chen, C.
    Reece, D.
    Chang, H.
    MODERN PATHOLOGY, 2010, 23 : 317A - 317A
12345